Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
As Executive Vice-Chair Samina Hamied Moves To Non-Exec Role
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
